Astrocyte Pharmaceuticals

Light Within the Black Hole of Concussion Therapeutics

Leslie BHA2025-02-17T14:27:23-05:00Last September, the Fédération Internationale de Football Association (FIFA) and the World Health Organization launched the “Suspect and Protect” concussion awareness campaign. In the past few years, the U.S. Department of Defense, the National Hockey League, and the National Football League each introduced plans to minimize concussions, including updating their concussion protocols. And large pharmaceutical companies have done…little. For companies active in this space, their slow progress may be more related to investors’ misperceptions of the topic than the science itself....

When ‘time is brain’

Antonette Ho2025-02-16T17:22:54-05:00...Now Lechleiter and his teammates at Astrocyte Pharmaceuticals — to which UT Health San Antonio has given exclusive licensing rights to develop the drug — are preparing for phase 2 clinical trials. These trials will focus on evaluating the effectiveness of AST-004 in reducing brain tissue loss in patients with large occlusion strokes, a severe type of stroke where blood clots cause substantial brain damage. Read more >>

Game-Changing Neuroprotection: Astrocyte Pharmaceuticals Breakthrough in Brain Injury Treatment

Leslie BHA2024-09-30T02:06:12-04:00"The air is crisp, and the sounds of whistles fill the air. The excitement is tangible as football, soccer, and other fall sports go into full swing. Yet behind the scenes of every game is the harsh reality of what happens when an athlete takes a hit—a momentary blackout, disorientation, and the fear of lasting damage. For too long, the best available treatments for concussions and brain injuries have been limited to rest and observation. Astrocyte Pharma, however,...

Murphy Highlights Groton’s Astrocyte Pharmaceuticals As “Innovator Of The Month”

Antonette Ho2024-09-02T17:32:37-04:00HARTFORD–U.S. Senator Chris Murphy (D-Conn.) on Monday announced that Astrocyte Pharmaceuticals, a Groton-based clinical-stage biopharmaceuticals company, was named “Innovator of the Month” for their work to advance cerebroprotective therapies for individuals suffering from stroke, traumatic brain injury (TBI), concussions and other neurodegenerative ailments. Astrocyte’s flagship program, AST-004, has been shown to significantly reduce early brain damage in a broad range of preclinical studies and is advancing to Phase 2 patient clinical trials next year. Astrocyte is breaking new ground with...

Game On for Concussion Therapies

Antonette Ho2024-03-10T00:44:19-05:00Most concussions—mild traumatic brain injuries (TBIs)—aren’t treated. Only a fraction of people who experience concussions seek help, and those who do usually are only prescribed rest. For about 20 percent, however, rest doesn’t alleviate the symptoms. Those symptoms may persist for months or years, making daily life difficult. As yet, there is no FDA-approved treatment for mild TBI. A few companies are addressing this increasingly-acknowledged problem by developing treatments that actually target the injury itself rather than just the resulting...

Alzheimer’s Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004

Antonette Ho2023-08-23T00:52:36-04:00Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors. The funding will accelerate the clinical development of AST-004, a highly promising therapeutic candidate aimed at treating a broad array of acute brain injuries including stroke and traumatic brain injury (TBI), and further...

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke

Antonette Ho2023-04-17T00:32:49-04:00Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today announced that Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Progress and Innovation Award from the journal Stroke for authoring one of the journal’s top three publications in 2022. The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.” Dr. Liston’s...

Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries

Antonette Ho2023-04-13T10:24:37-04:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers. This adaptive-design clinical study will be conducted over the next four to six months at the QPS clinical research site in Groningen, Netherlands. AST-004 is a small molecule adenosine A3/A1 receptor agonist that has consistently shown promising cerebroprotective results...

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium

Ziad2022-11-25T13:59:44-05:00Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study. Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held...

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Ziad2022-11-25T13:59:45-05:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004. The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke and traumatic brain injury (TBI) victims, and as a chronic treatment for neurodegenerative diseases like Alzheimer’s. AST-004 has demonstrated a broad range of cerebroprotective efficacy when treating...